According to filings with the U.S. Securities and Exchange Commission, Nirrin Technologies is raising up to $9,711,196.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Nirrin Technologies
Nirrin advances bioprocess analytics with high-precision tunable laser spectroscopy, delivering direct, quantitative measurements from development through manufacturing. TALOS provides rapid protein quantitation without dilution or calibration curves, while ATLAS enables multi-analyte measurement of proteins, buffers, and excipients in complex bioprocess and formulation samples. Our systems help bioprocess teams generate trustworthy data, simplify workflows, and make better manufacturing decisions.

To learn more, visit https://www.nirrin.tech/
LinkedIn: https://www.linkedin.com/company/nirrin/

Contact:
Bryan Hassell, Chief Executive Officer
https://www.linkedin.com/in/bryanhassell/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.